Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport

Zhe Sheng Chen, Robert W. Robey, Martin G. Belinsky, Irina Shchaveleva, Xiao Qin Ren, Yoshikazu Sugimoto, Douglas D. Ross, Susan E. Bates, Gary D. Kruh

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

ABCG2 is a plasma membrane efflux pump that is able to confer resistance to several anticancer agents, including mitoxantrone, camptothecins, anthracyclines, and flavopiridol. The antimetabolite methotrexate (MTX) was inferred recently to be an additional substrate of the pump based on the analysis of ABCG2-overexpressing cell lines. However, the transport characteristics of the pump with regard to this agent have not been determined. In addition, physiological substrates of ABCG2 have not been identified. Here we examine the in vitro transport properties of the pump using membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector. In so doing it is shown that MTX is a high capacity low affinity substrate of the pump, with Km and Vmax values of 1.34 ± 0.18 mM and 687 ± 87 pmol/mg/min, respectively. Unlike previously characterized multidrug resistance protein family members, ABCG2 is also able to transport MTX diglutamate and MTX triglutamate. However, addition of even one more glutamyl residue is sufficient to completely abrogate ABCG2-mediated transport. By contrast with the wild-type protein (ABCG2-R482), two ABCG2 variants that have been identified in drug selected cell lines, R482T and R482G, were unable to transport MTX to any extent. Similarly, folic acid was subject to efflux by the wild-type protein but not by the two mutants. However, transport of the reduced folate leucovorin was not detected for either the wild-type or the mutant proteins. Finally, it is shown that ABCG2 is capable of transporting E217βG with Km and Vmax values of 44.2 ± 4.3 μM and 103 ± 17 pmol/mg/min, respectively. These results indicate that ABCG2 is a component of the energy-dependent efflux system for certain folates and antifolates, but that its transport characteristics with respect to polyglutamates and reduced folates are not identical to those of multidrug resistance protein family members. In addition, it is demonstrated that R482 mutations observed in drug-resistant cell lines have profound effects on the in vitro transport properties of the pump.

Original languageEnglish
Pages (from-to)4048-4054
Number of pages7
JournalCancer Research
Volume63
Issue number14
Publication statusPublished - 2003 Jul 15
Externally publishedYes

Fingerprint

Glucuronides
Methotrexate
Estradiol
Folic Acid
P-Glycoproteins
Mutation
alvocidib
Cell Line
Pteroylpolyglutamic Acids
Folic Acid Antagonists
Antimetabolites
Camptothecin
Mitoxantrone
Leucovorin
HEK293 Cells
Anthracyclines
Mutant Proteins
Pharmaceutical Preparations
Antineoplastic Agents
Cell Membrane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2 : Effects of acquired mutations at R482 on methotrexate transport. / Chen, Zhe Sheng; Robey, Robert W.; Belinsky, Martin G.; Shchaveleva, Irina; Ren, Xiao Qin; Sugimoto, Yoshikazu; Ross, Douglas D.; Bates, Susan E.; Kruh, Gary D.

In: Cancer Research, Vol. 63, No. 14, 15.07.2003, p. 4048-4054.

Research output: Contribution to journalArticle

Chen, ZS, Robey, RW, Belinsky, MG, Shchaveleva, I, Ren, XQ, Sugimoto, Y, Ross, DD, Bates, SE & Kruh, GD 2003, 'Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport', Cancer Research, vol. 63, no. 14, pp. 4048-4054.
Chen, Zhe Sheng ; Robey, Robert W. ; Belinsky, Martin G. ; Shchaveleva, Irina ; Ren, Xiao Qin ; Sugimoto, Yoshikazu ; Ross, Douglas D. ; Bates, Susan E. ; Kruh, Gary D. / Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2 : Effects of acquired mutations at R482 on methotrexate transport. In: Cancer Research. 2003 ; Vol. 63, No. 14. pp. 4048-4054.
@article{9707fb30c750435e9ee8a62e3f4a563f,
title = "Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport",
abstract = "ABCG2 is a plasma membrane efflux pump that is able to confer resistance to several anticancer agents, including mitoxantrone, camptothecins, anthracyclines, and flavopiridol. The antimetabolite methotrexate (MTX) was inferred recently to be an additional substrate of the pump based on the analysis of ABCG2-overexpressing cell lines. However, the transport characteristics of the pump with regard to this agent have not been determined. In addition, physiological substrates of ABCG2 have not been identified. Here we examine the in vitro transport properties of the pump using membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector. In so doing it is shown that MTX is a high capacity low affinity substrate of the pump, with Km and Vmax values of 1.34 ± 0.18 mM and 687 ± 87 pmol/mg/min, respectively. Unlike previously characterized multidrug resistance protein family members, ABCG2 is also able to transport MTX diglutamate and MTX triglutamate. However, addition of even one more glutamyl residue is sufficient to completely abrogate ABCG2-mediated transport. By contrast with the wild-type protein (ABCG2-R482), two ABCG2 variants that have been identified in drug selected cell lines, R482T and R482G, were unable to transport MTX to any extent. Similarly, folic acid was subject to efflux by the wild-type protein but not by the two mutants. However, transport of the reduced folate leucovorin was not detected for either the wild-type or the mutant proteins. Finally, it is shown that ABCG2 is capable of transporting E217βG with Km and Vmax values of 44.2 ± 4.3 μM and 103 ± 17 pmol/mg/min, respectively. These results indicate that ABCG2 is a component of the energy-dependent efflux system for certain folates and antifolates, but that its transport characteristics with respect to polyglutamates and reduced folates are not identical to those of multidrug resistance protein family members. In addition, it is demonstrated that R482 mutations observed in drug-resistant cell lines have profound effects on the in vitro transport properties of the pump.",
author = "Chen, {Zhe Sheng} and Robey, {Robert W.} and Belinsky, {Martin G.} and Irina Shchaveleva and Ren, {Xiao Qin} and Yoshikazu Sugimoto and Ross, {Douglas D.} and Bates, {Susan E.} and Kruh, {Gary D.}",
year = "2003",
month = "7",
day = "15",
language = "English",
volume = "63",
pages = "4048--4054",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2

T2 - Effects of acquired mutations at R482 on methotrexate transport

AU - Chen, Zhe Sheng

AU - Robey, Robert W.

AU - Belinsky, Martin G.

AU - Shchaveleva, Irina

AU - Ren, Xiao Qin

AU - Sugimoto, Yoshikazu

AU - Ross, Douglas D.

AU - Bates, Susan E.

AU - Kruh, Gary D.

PY - 2003/7/15

Y1 - 2003/7/15

N2 - ABCG2 is a plasma membrane efflux pump that is able to confer resistance to several anticancer agents, including mitoxantrone, camptothecins, anthracyclines, and flavopiridol. The antimetabolite methotrexate (MTX) was inferred recently to be an additional substrate of the pump based on the analysis of ABCG2-overexpressing cell lines. However, the transport characteristics of the pump with regard to this agent have not been determined. In addition, physiological substrates of ABCG2 have not been identified. Here we examine the in vitro transport properties of the pump using membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector. In so doing it is shown that MTX is a high capacity low affinity substrate of the pump, with Km and Vmax values of 1.34 ± 0.18 mM and 687 ± 87 pmol/mg/min, respectively. Unlike previously characterized multidrug resistance protein family members, ABCG2 is also able to transport MTX diglutamate and MTX triglutamate. However, addition of even one more glutamyl residue is sufficient to completely abrogate ABCG2-mediated transport. By contrast with the wild-type protein (ABCG2-R482), two ABCG2 variants that have been identified in drug selected cell lines, R482T and R482G, were unable to transport MTX to any extent. Similarly, folic acid was subject to efflux by the wild-type protein but not by the two mutants. However, transport of the reduced folate leucovorin was not detected for either the wild-type or the mutant proteins. Finally, it is shown that ABCG2 is capable of transporting E217βG with Km and Vmax values of 44.2 ± 4.3 μM and 103 ± 17 pmol/mg/min, respectively. These results indicate that ABCG2 is a component of the energy-dependent efflux system for certain folates and antifolates, but that its transport characteristics with respect to polyglutamates and reduced folates are not identical to those of multidrug resistance protein family members. In addition, it is demonstrated that R482 mutations observed in drug-resistant cell lines have profound effects on the in vitro transport properties of the pump.

AB - ABCG2 is a plasma membrane efflux pump that is able to confer resistance to several anticancer agents, including mitoxantrone, camptothecins, anthracyclines, and flavopiridol. The antimetabolite methotrexate (MTX) was inferred recently to be an additional substrate of the pump based on the analysis of ABCG2-overexpressing cell lines. However, the transport characteristics of the pump with regard to this agent have not been determined. In addition, physiological substrates of ABCG2 have not been identified. Here we examine the in vitro transport properties of the pump using membrane vesicles prepared from HEK293 cells transfected with ABCG2 expression vector. In so doing it is shown that MTX is a high capacity low affinity substrate of the pump, with Km and Vmax values of 1.34 ± 0.18 mM and 687 ± 87 pmol/mg/min, respectively. Unlike previously characterized multidrug resistance protein family members, ABCG2 is also able to transport MTX diglutamate and MTX triglutamate. However, addition of even one more glutamyl residue is sufficient to completely abrogate ABCG2-mediated transport. By contrast with the wild-type protein (ABCG2-R482), two ABCG2 variants that have been identified in drug selected cell lines, R482T and R482G, were unable to transport MTX to any extent. Similarly, folic acid was subject to efflux by the wild-type protein but not by the two mutants. However, transport of the reduced folate leucovorin was not detected for either the wild-type or the mutant proteins. Finally, it is shown that ABCG2 is capable of transporting E217βG with Km and Vmax values of 44.2 ± 4.3 μM and 103 ± 17 pmol/mg/min, respectively. These results indicate that ABCG2 is a component of the energy-dependent efflux system for certain folates and antifolates, but that its transport characteristics with respect to polyglutamates and reduced folates are not identical to those of multidrug resistance protein family members. In addition, it is demonstrated that R482 mutations observed in drug-resistant cell lines have profound effects on the in vitro transport properties of the pump.

UR - http://www.scopus.com/inward/record.url?scp=0042354831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042354831&partnerID=8YFLogxK

M3 - Article

C2 - 12874005

AN - SCOPUS:0042354831

VL - 63

SP - 4048

EP - 4054

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -